https://www.direnzo.biz/it/en/Di Renzo Regulatory Affairs podcast for pharmaceutical companies, for manufacturers of medical devices, cosmetics, food supplements and disinfectants. News from our blog and from our weekly magazine ISI, Information Health.]]>enEntrepreneurshipDi Renzo Regulatrory Affairshttps://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/2cf30b6e5225fb4a7106d492a1832837.jpghttps://www.direnzo.biz/it/en/Mon, 07 Sep 2026 09:32:27 +0000Di Renzo Regulatrory AffairsDi Renzo Regulatrory Affairsinfo@direnzo.bizThe https://www.direnzo.biz podcast for pharmaceutical companies, for manufacturers of medical devices, cosmetics, food supplements and disinfectants. News from our blog and from our weekly magazine ISI, Information Health.Di Renzo Regulatory Affairs podcast for pharmaceutical companies, for manufacturers of medical devices, cosmetics, food supplements and disinfectants. News from our blog and from our weekly magazine ISI, Information Health.]]>false3b26a695-2d74-546a-a8d9-dbac5a68a07fepisodichttps://www.spreaker.com/episode/ai-and-promotional-materials-in-the-pharma-sector-the-new-aifa-guidelines--74959377AIFA Guidelines published by the Drug Information and Advertising Vigilance Unit.What we cover in this episode:

• Responsibility remains unchanged: Why the use of AI does not alter the nature of promotional material nor the obligations of the Marketing Authorization Holder (MAH) and the Scientific Service Responsible Person (RSS).
• Certified sources and verifiability: The requirement to rely strictly on official sources (such as the SmPC) and to rigorously verify outputs to prevent hallucinations or incorrect citations.
• The Human-in-the-Loop principle: The central role of human oversight at every stage of the process and the requirements within the Quality Management System.
• Chatbots and Virtual Assistants: Information obligations toward healthcare professionals, transparency, and specific disclaimers for direct-interaction tools.
• Traceability in AIFA submissions: New mandatory information for the submission sheet and the required validation declaration from the Scientific Service Responsible Person.

Visit the original article on Di Renzo Regulatory Affairs to explore all the regulatory details.]]>https://api.spreaker.com/episode/74959377Mon, 07 Sep 2026 09:16:03 +0000Di Renzo Regulatrory AffairsGenerative Artificial Intelligence is transforming the way pharmaceutical companies create content and scientific information. But how can technological innovation be reconciled with the current regulatory framework?In this new podcast episode, we...AIFA Guidelines published by the Drug Information and Advertising Vigilance Unit.What we cover in this episode:

• Responsibility remains unchanged: Why the use of AI does not alter the nature of promotional material nor the obligations of the Marketing Authorization Holder (MAH) and the Scientific Service Responsible Person (RSS).
• Certified sources and verifiability: The requirement to rely strictly on official sources (such as the SmPC) and to rigorously verify outputs to prevent hallucinations or incorrect citations.
• The Human-in-the-Loop principle: The central role of human oversight at every stage of the process and the requirements within the Quality Management System.
• Chatbots and Virtual Assistants: Information obligations toward healthcare professionals, transparency, and specific disclaimers for direct-interaction tools.
• Traceability in AIFA submissions: New mandatory information for the submission sheet and the required validation declaration from the Scientific Service Responsible Person.

Visit the original article on Di Renzo Regulatory Affairs to explore all the regulatory details.]]>703ai,intelligence,pharmaceuticalfalse311fullhttps://en.direnzo.biz/echa-guideline/Substances of Concern (SoC) in biocidal products under the Biocidal Products Regulation (BPR - Regulation EU No 528/2012).In this episode, we break down this major regulatory update and what it means for the chemical and manufacturing industries.]]>https://api.spreaker.com/episode/73143364Fri, 24 Jul 2026 10:57:13 +0000Di Renzo Regulatrory AffairsThe European Chemicals Agency (ECHA) has released a new draft guidance dedicated entirely to the identification and assessment of https://en.direnzo.biz/echa-guideline/ (SoC) in biocidal products under the Biocidal Products Regulation (BPR -...Substances of Concern (SoC) in biocidal products under the Biocidal Products Regulation (BPR - Regulation EU No 528/2012).In this episode, we break down this major regulatory update and what it means for the chemical and manufacturing industries.]]>562false310fullhttps://www.spreaker.com/episode/mdr-turning-point-what-changes-with-the-proposed-revision-of-the-medical-device-regulation--72963656COM(2025)1023, Europe aims to cut red tape and boost the competitiveness of the medical sector—without compromising the strict safety standards of medical devices.In this podcast episode, we analyze the impact of this upcoming revision on manufacturers and industry operators.What we discuss in this episode:

• Process Digitalization: How the transition to electronic documentation and digital workflows (linked to EUDAMED) will reduce the paperwork burden.
• Flexibility for the PRRC: New opportunities for regulatory outsourcing—a breath of fresh air, especially for SMEs.
• Streamlining vs. Safety: What is changing on the administrative front and why clinical evaluation and post-market surveillance requirements remain as strict and unchanged as ever.
• Ongoing Challenges: The limited capacity of Notified Bodies and the structural bottlenecks that have yet to be resolved.

🎧 Tune in to find out how to guide your business through this regulatory evolution!📌 To delve deeper into the topic, read our full blog post: Revision of Regulation (EU) 2017/745 (MDR): Impact on Manufacturers]]>https://api.spreaker.com/episode/72963656Tue, 14 Jul 2026 08:29:43 +0000Di Renzo Regulatrory AffairsA few years after the entry into force of Regulation (EU) 2017/745 (MDR), the European Commission is taking action to make the system more sustainable. With the amendment proposal COM(2025)1023, Europe aims to cut red tape and boost the...COM(2025)1023, Europe aims to cut red tape and boost the competitiveness of the medical sector—without compromising the strict safety standards of medical devices.In this podcast episode, we analyze the impact of this upcoming revision on manufacturers and industry operators.What we discuss in this episode:

• Process Digitalization: How the transition to electronic documentation and digital workflows (linked to EUDAMED) will reduce the paperwork burden.
• Flexibility for the PRRC: New opportunities for regulatory outsourcing—a breath of fresh air, especially for SMEs.
• Streamlining vs. Safety: What is changing on the administrative front and why clinical evaluation and post-market surveillance requirements remain as strict and unchanged as ever.
• Ongoing Challenges: The limited capacity of Notified Bodies and the structural bottlenecks that have yet to be resolved.

🎧 Tune in to find out how to guide your business through this regulatory evolution!📌 To delve deeper into the topic, read our full blog post: Revision of Regulation (EU) 2017/745 (MDR): Impact on Manufacturers]]>518mdr,medicaldevicesfalse39fullhttps://www.spreaker.com/episode/eudamed-and-udi-codes-a-practical-guide-to-getting-it-right--72805462EUDAMED registration (registrazione eudamed) without running into compliance roadblocks.We will break down the system's operational phases, explaining how to structure your data and correctly assign the UDI code (codice udi)—from the Basic UDI-DI all the way down to individual commercial packaging—to ensure full traceability and compliance with MDR and IVDR regulations. Whether you are a manufacturer, authorized representative, or importer, discover practical tips and essential steps to optimize your company's workflow and avoid bureaucratic delays.Happy listening!Listen to the episode and leave a comment with your regulatory questions.]]>https://api.spreaker.com/episode/72805462Fri, 03 Jul 2026 13:45:03 +0000Di Renzo Regulatrory AffairsAs deadlines approach and new European obligations take effect, the proper management of medical devices requires unprecedented attention. In this episode, we clear up everything you need to know to successfully navigate EUDAMED registration...EUDAMED registration (registrazione eudamed) without running into compliance roadblocks.We will break down the system's operational phases, explaining how to structure your data and correctly assign the UDI code (codice udi)—from the Basic UDI-DI all the way down to individual commercial packaging—to ensure full traceability and compliance with MDR and IVDR regulations. Whether you are a manufacturer, authorized representative, or importer, discover practical tips and essential steps to optimize your company's workflow and avoid bureaucratic delays.Happy listening!Listen to the episode and leave a comment with your regulatory questions.]]>559code,database,eudamed,medicaldevices,udifalse38fullhttps://www.spreaker.com/episode/importers-and-distributors-when-do-manufacturers-obligations-start-mdr-ivdr--72153726In this episode, we shed light on one of the most complex, sensitive, and controversial aspects of the European Regulation on Medical Devices (MDR 2017/745) and the European Regulation on In Vitro Diagnostics (IVDR 2017/746): Article 16.
If you work in logistics, distribution, import, or compliance in the MedTech sector, you can't miss this episode.

Let's analyze together:

👉 The 3 key scenarios in which the automatic change of legal role is triggered.
👉 The key exceptions (when label translation and repackaging do not alter your qualifications).
👉 The strict additional obligations for those who repackage (28-day advance notification and Quality Management System Certification).

Avoiding sanctions or customs blockades on the market requires a thorough understanding of your economic roles. Listen to the episode to find out how to protect your business!

Enjoy!]]>https://api.spreaker.com/episode/72153726Mon, 25 May 2026 12:25:20 +0000Di Renzo Regulatrory AffairsWhen does a distributor or importer become, for all legal purposes, the MANUFACTURER of a medical device? In this episode, we shed light on one of the most complex, sensitive, and controversial aspects of the European Regulation on Medical Devices...In this episode, we shed light on one of the most complex, sensitive, and controversial aspects of the European Regulation on Medical Devices (MDR 2017/745) and the European Regulation on In Vitro Diagnostics (IVDR 2017/746): Article 16.
If you work in logistics, distribution, import, or compliance in the MedTech sector, you can't miss this episode.

Let's analyze together:

👉 The 3 key scenarios in which the automatic change of legal role is triggered.
👉 The key exceptions (when label translation and repackaging do not alter your qualifications).
👉 The strict additional obligations for those who repackage (28-day advance notification and Quality Management System Certification).

Avoiding sanctions or customs blockades on the market requires a thorough understanding of your economic roles. Listen to the episode to find out how to protect your business!

Enjoy!]]>409devices,medicalfalse37fullhttps://en.direnzo.biz/pharmaceutical-gmp-audit/Together with industry professionals, we analyze why these inspections aren't just bureaucratic procedures, but rather true safeguards for public health and business stability. We'll discover the concrete benefits for companies (and marketing authorization holders), what auditors really look for when they enter a manufacturing facility, and why—after the pandemic—on-site inspections have once again become an indispensable requirement compared to remote digital controls.
If you work in the regulatory or quality sectors, or simply want to understand the rigorous standards behind the production of a human or veterinary medicinal product, this is the episode for you!]]>https://api.spreaker.com/episode/72114568Fri, 22 May 2026 13:05:33 +0000Di Renzo Regulatrory AffairsWhat happens before a drug reaches our hands or those of our animals? In this episode, we explore the beating heart of safety and compliance: GMP (Good Manufacturing Practice) audits in the pharmaceutical industry. Together with industry...Together with industry professionals, we analyze why these inspections aren't just bureaucratic procedures, but rather true safeguards for public health and business stability. We'll discover the concrete benefits for companies (and marketing authorization holders), what auditors really look for when they enter a manufacturing facility, and why—after the pandemic—on-site inspections have once again become an indispensable requirement compared to remote digital controls.
If you work in the regulatory or quality sectors, or simply want to understand the rigorous standards behind the production of a human or veterinary medicinal product, this is the episode for you!]]>401false36fullhttps://en.direnzo.biz/drug-shortages-aifa-regulations-aic-holders/

• Mandatory communication timelines and procedures.
• Penalties for failure to notify.
• Operational strategies to prevent disruptions in patient care.

Essential listening for Regulatory Affairs and Quality Assurance professionals.
🎧 Listen to the episode now to stay compliant and informed!]]>https://api.spreaker.com/episode/70776246Fri, 20 Mar 2026 10:05:46 +0000Di Renzo Regulatrory AffairsManaging shortages is more than just a logistical challenge; it is a complex web of regulatory obligations. In this episode, we analyze the latest AIFA (Italian Medicines Agency) provisions and the specific responsibilities of Marketing Authorization...

• Mandatory communication timelines and procedures.
• Penalties for failure to notify.
• Operational strategies to prevent disruptions in patient care.

Essential listening for Regulatory Affairs and Quality Assurance professionals.
🎧 Listen to the episode now to stay compliant and informed!]]>515false35fullhttps://en.direnzo.biz/sop-otc-aifa-guidelines/Non-Prescription Medicines) and OTC (Over-the-Counter) drugs requires surgical attention to regulatory details. In this episode, we explore the key points of the AIFA guidelines:
✅ Medicine classification. 
✅ Requirements for online sales.
✅ Sticker layouts and mandatory labeling.An essential episode for Regulatory Affairs Managers and industry consultants. Enjoy the listen!]]>https://api.spreaker.com/episode/70502696Fri, 06 Mar 2026 08:48:58 +0000Di Renzo Regulatrory AffairsManaging SOP (https://en.direnzo.biz/sop-otc-aifa-guidelines/) and OTC (Over-the-Counter) drugs requires surgical attention to regulatory details. In this episode, we explore the key points of the AIFA guidelines: ✅ Medicine classification.  ✅...Non-Prescription Medicines) and OTC (Over-the-Counter) drugs requires surgical attention to regulatory details. In this episode, we explore the key points of the AIFA guidelines:
✅ Medicine classification. 
✅ Requirements for online sales.
✅ Sticker layouts and mandatory labeling.An essential episode for Regulatory Affairs Managers and industry consultants. Enjoy the listen!]]>542aifa,otc,pharmaceutical,sopfalse34fullhttps://en.direnzo.biz/pharmaceutical-packaging-design-regulatory/Pharma and Healthcare sectors, a graphic error is more than just an aesthetic flaw—it’s a significant legal risk. In this episode, we analyze why the design of pharmaceuticals, supplements, and medical devices must go hand-in-hand with Regulatory Affairs.Join our experts as we explore:

• Pharmaceutical Sector: Managing artwork and the surgical precision required for patient information leaflets (PILs).
• Dietary Supplements: How to communicate benefits (claims) without violating government regulations.
• Medical Devices & Cosmetics: From CE marking to the correct management of INCI lists.
• Advertising: The strategic advantage of creating healthcare advertising that is "compliant by design" to avoid penalties and speed up time-to-market.

Learn how to transform regulatory constraints into a competitive advantage for your brand. If you work in marketing, quality assurance, or regulatory affairs, this episode is for you.📌 Want to dive deeper? Visit our website to read the full article and discover our compliant packaging design services.]]>https://api.spreaker.com/episode/69839977Fri, 06 Feb 2026 07:56:42 +0000Di Renzo Regulatrory AffairsIn the Pharma and Healthcare sectors, a graphic error is more than just an aesthetic flaw—it’s a significant legal risk. In this episode, we analyze why the design of pharmaceuticals, supplements, and medical devices must go hand-in-hand with...Pharma and Healthcare sectors, a graphic error is more than just an aesthetic flaw—it’s a significant legal risk. In this episode, we analyze why the design of pharmaceuticals, supplements, and medical devices must go hand-in-hand with Regulatory Affairs.Join our experts as we explore:

• Pharmaceutical Sector: Managing artwork and the surgical precision required for patient information leaflets (PILs).
• Dietary Supplements: How to communicate benefits (claims) without violating government regulations.
• Medical Devices & Cosmetics: From CE marking to the correct management of INCI lists.
• Advertising: The strategic advantage of creating healthcare advertising that is "compliant by design" to avoid penalties and speed up time-to-market.

Learn how to transform regulatory constraints into a competitive advantage for your brand. If you work in marketing, quality assurance, or regulatory affairs, this episode is for you.📌 Want to dive deeper? Visit our website to read the full article and discover our compliant packaging design services.]]>317graphics,healt,packagingfalse33fullhttps://en.direnzo.biz/adaptation-of-new-veterinary-gmps/new veterinary GMPs (Good Manufacturing Practices) introduced by Regulation (EU) 2019/6 and subsequent directives.We explore the key points from the article by Di Renzo Regulatory Affairs, focusing on:

• The primary differences compared to standards for medicinal products for human use.
• Requirements for manufacturing, importation, and pharmacovigilance.
• Critical deadlines and the importance of a risk-based approach.

Essential listening for Quality Managers, industry professionals, and companies operating within the animal health market.]]>https://api.spreaker.com/episode/69741902Mon, 02 Feb 2026 15:29:55 +0000Di Renzo Regulatrory AffairsThe veterinary medicinal products sector is undergoing an unprecedented regulatory transformation. In this episode, we analyze the adaptation to the https://en.direnzo.biz/adaptation-of-new-veterinary-gmps/ (Good Manufacturing Practices) introduced by...new veterinary GMPs (Good Manufacturing Practices) introduced by Regulation (EU) 2019/6 and subsequent directives.We explore the key points from the article by Di Renzo Regulatory Affairs, focusing on:

• The primary differences compared to standards for medicinal products for human use.
• Requirements for manufacturing, importation, and pharmacovigilance.
• Critical deadlines and the importance of a risk-based approach.

Essential listening for Quality Managers, industry professionals, and companies operating within the animal health market.]]>374gmp,veterinaryfalse32fullhttps://www.spreaker.com/episode/acc-system-the-new-rules-for-intermediate-dates--69591570Description: In this episode, we analyze the recent technical updates to the Conventions and Congresses Authorization System (ACC), effective January 19. The introduction of the "Intermediate Dates" field is more than just a software update; it is a new procedural requirement impacting compliance for pharma companies and providers.Join the experts at Di Renzo Regulatory Affairs as we dive into:

• Technical Specs: How to enter intermediate dates and when it is unnecessary (e.g., 365-day FAD).
• Time Constraints: Mandatory deadlines for calendar changes (FAQ no. 32).
• Managing Discrepancies: Preventing Agency RFIs through correct scientific program mapping.
• Compliance Strategy: The role of Regulatory departments in ensuring a smooth authorization flow.

Useful Links: 📌 Full Article: https://en.direnzo.biz/update-congress-conventions/
]]>https://api.spreaker.com/episode/69591570Mon, 26 Jan 2026 14:32:56 +0000Di Renzo Regulatrory AffairsDescription: In this episode, we analyze the recent technical updates to the Conventions and Congresses Authorization System (ACC), effective January 19. The introduction of the "Intermediate Dates" field is more than just a software update; it is a...Description: In this episode, we analyze the recent technical updates to the Conventions and Congresses Authorization System (ACC), effective January 19. The introduction of the "Intermediate Dates" field is more than just a software update; it is a new procedural requirement impacting compliance for pharma companies and providers.Join the experts at Di Renzo Regulatory Affairs as we dive into:

• Technical Specs: How to enter intermediate dates and when it is unnecessary (e.g., 365-day FAD).
• Time Constraints: Mandatory deadlines for calendar changes (FAQ no. 32).
• Managing Discrepancies: Preventing Agency RFIs through correct scientific program mapping.
• Compliance Strategy: The role of Regulatory departments in ensuring a smooth authorization flow.

Useful Links: 📌 Full Article: https://en.direnzo.biz/update-congress-conventions/
]]>264false31fullhttps://en.direnzo.biz/orphan-drugs-description/market challenge for pharmaceutical companies and the crucial role of the European Regulation (EC 141/2000). Discover how the 'Orphan Drug' designation and incentives are changing the lives of patients with rare diseases. Don't miss it! 👇
https://en.direnzo.biz/orphan-drugs-description/

OrphanDrugs #PharmaceuticalRegulation #EMA #Innovation #HealthPodcast
]]>https://api.spreaker.com/episode/68833340Tue, 02 Dec 2025 15:49:55 +0000Di Renzo Regulatrory AffairsDeveloping Orphan Drugs is a true undertaking! 🧐 In our latest episode, we dive deep into the market challenge for pharmaceutical companies and the crucial role of the European Regulation (EC 141/2000). Discover how the 'Orphan Drug' designation and...market challenge for pharmaceutical companies and the crucial role of the European Regulation (EC 141/2000). Discover how the 'Orphan Drug' designation and incentives are changing the lives of patients with rare diseases. Don't miss it! 👇
https://en.direnzo.biz/orphan-drugs-description/

OrphanDrugs #PharmaceuticalRegulation #EMA #Innovation #HealthPodcast
]]>381ema,healthpodcast,orphandrugs,pharmaceuticalregulationfalse223fullhttps://en.direnzo.biz/eudamed-udi-obligation-may-2026/UDI registration in EUDAMED will become mandatory for all medical devices marketed in the EU. What does this mean for manufacturers, importers and Regulatory Affairs professionals? Find out in the new episode as we break down deadlines, obligations and the practical impact of the latest EU decisions.]]>https://api.spreaker.com/episode/68785433Fri, 28 Nov 2025 14:25:41 +0000Di Renzo Regulatrory Affairs🗓️ Starting 28 May 2026, https://en.direnzo.biz/eudamed-udi-obligation-may-2026/ in EUDAMED will become mandatory for all medical devices marketed in the EU. What does this mean for manufacturers, importers and Regulatory Affairs professionals? Find...UDI registration in EUDAMED will become mandatory for all medical devices marketed in the EU. What does this mean for manufacturers, importers and Regulatory Affairs professionals? Find out in the new episode as we break down deadlines, obligations and the practical impact of the latest EU decisions.]]>250devices,eudamed,medicalfalse222fullhttps://en.direnzo.biz/ema-update-pms-database/
A must-listen for professionals in regulatory affairs across pharma. Don’t miss it!

#regulatoryaffairs #PMS #EMA #pharma #regulatoryconsulting]]>https://api.spreaker.com/episode/68534619Wed, 12 Nov 2025 11:18:03 +0000Di Renzo Regulatrory AffairsNew podcast episode out now! Let’s dive into the latest updates from the European Medicines Agency (EMA) on the Product Management Service (PMS) database — key changes on the XEVMPD migration, deadlines, ISO-IDMP requirements, and their impact on...
A must-listen for professionals in regulatory affairs across pharma. Don’t miss it!

#regulatoryaffairs #PMS #EMA #pharma #regulatoryconsulting]]>396false221fullhttps://en.direnzo.biz/biocides-guideline/Regulation (EU) 528/2012 (BPR), the European framework that regulates the placing on the market and use of biocidal products. We’ll explore the differences between the Directive and the Regulation, the role of PMCs in Italy, and the new obligations for businesses. Step by step, we will discuss how to obtain authorization, ensure compliant labeling and advertising, and successfully manage the regulatory transition. An essential episode for manufacturers, importers, and industry professionals who want to stay up to date and compliant.]]>https://api.spreaker.com/episode/67997585Fri, 03 Oct 2025 09:49:08 +0000Di Renzo Regulatrory AffairsIn this episode, we clarify the transition from Directive 98/8/EC to https://en.direnzo.biz/biocides-guideline/, the European framework that regulates the placing on the market and use of biocidal products. We’ll explore the differences between the...Regulation (EU) 528/2012 (BPR), the European framework that regulates the placing on the market and use of biocidal products. We’ll explore the differences between the Directive and the Regulation, the role of PMCs in Italy, and the new obligations for businesses. Step by step, we will discuss how to obtain authorization, ensure compliant labeling and advertising, and successfully manage the regulatory transition. An essential episode for manufacturers, importers, and industry professionals who want to stay up to date and compliant.]]>498biocides,europeanfalse220fullhttps://en.direnzo.biz/new-version-mir-7-3-1/MIR 7.3.1) is now available and will become mandatory in the EU and Switzerland starting November 2025 for the reporting of serious incidents involving medical devices and IVDs. In this episode we cover:

• the main updates (new fields, IMDRF codes, geographical and technical changes);
• key differences from the previous version;
• what manufacturers should do now to prepare.

A must-listen to stay ahead of the changes and ensure compliance by the deadline.]]>https://api.spreaker.com/episode/67819436Fri, 19 Sep 2025 08:56:05 +0000Di Renzo Regulatrory AffairsThe new version of the Manufacturer Incident Report (https://en.direnzo.biz/new-version-mir-7-3-1/) is now available and will become mandatory in the EU and Switzerland starting November 2025 for the reporting of serious incidents involving medical...MIR 7.3.1) is now available and will become mandatory in the EU and Switzerland starting November 2025 for the reporting of serious incidents involving medical devices and IVDs. In this episode we cover:

• the main updates (new fields, IMDRF codes, geographical and technical changes);
• key differences from the previous version;
• what manufacturers should do now to prepare.

A must-listen to stay ahead of the changes and ensure compliance by the deadline.]]>306medicaldevices,mirfalse219fullhttps://www.spreaker.com/episode/pharmacovigilance-goes-social--67734928drug safety and real patient experiences. Join us as we explore:

• why social networks are a game-changer for collecting safety data,
• the regulatory and practical challenges of monitoring digital platforms,
• and how companies can turn social media into a reliable ally for pharmacovigilance.

If you work in pharma—or you’re simply curious about how the digital world is reshaping drug safety—this episode is for you.


https://www.direnzo.biz/it/en/pharmacovigilance-social-networks/]]>https://api.spreaker.com/episode/67734928Fri, 12 Sep 2025 13:38:56 +0000Di Renzo Regulatrory AffairsSocial media isn’t just about likes and shares anymore—it’s becoming a powerful tool in pharmacovigilance. In this episode of Regulatory Affairs & Life Science, we dive into how online conversations can reveal valuable insights about drug safety...drug safety and real patient experiences. Join us as we explore:

• why social networks are a game-changer for collecting safety data,
• the regulatory and practical challenges of monitoring digital platforms,
• and how companies can turn social media into a reliable ally for pharmacovigilance.

If you work in pharma—or you’re simply curious about how the digital world is reshaping drug safety—this episode is for you.


https://www.direnzo.biz/it/en/pharmacovigilance-social-networks/]]>329false218fullhttps://www.spreaker.com/episode/classification-of-medical-devices-in-italy--67465271registration under Italian law and the EU Medical Device Regulation (MDR 2017/745). We cover everything you need to know about the Italian medical device database, the Repertorio, the CND classification system, and the future role of EUDAMED. 🔑 Keywords & Topics:

• Medical device registration process
• Italian Ministry of Health requirements
• EU MDR compliance
• CND code and Repertorio explained
• EUDAMED implementation timeline
• Regulatory strategy for manufacturers and distributors

👩‍⚕️ Whether you’re a manufacturer, authorized representative, importer, distributor, PRRC or RAQA professional, this episode will help you avoid mistakes and stay compliant with the latest medical device regulations. 👉 Listen now and stay updated on regulatory affairs for medical devices.

#MedicalDevices #RegulatoryAffairs #MDR745 #EUDAMED #MedicalDeviceCompliance #HealthcareRegulation #RAQA #PRRC]]>https://api.spreaker.com/episode/67465271Thu, 21 Aug 2025 08:57:23 +0000Di Renzo Regulatrory AffairsIn this episode, we explore the essentials of medical device https://www.direnzo.biz/it/en/medical-device-italian-classification/#:~:text=As%20of%201%20January%202026,health%20system%20on%20medical%20devices. and the EU Medical Device Regulation (MDR...registration under Italian law and the EU Medical Device Regulation (MDR 2017/745). We cover everything you need to know about the Italian medical device database, the Repertorio, the CND classification system, and the future role of EUDAMED. 🔑 Keywords & Topics:

• Medical device registration process
• Italian Ministry of Health requirements
• EU MDR compliance
• CND code and Repertorio explained
• EUDAMED implementation timeline
• Regulatory strategy for manufacturers and distributors

👩‍⚕️ Whether you’re a manufacturer, authorized representative, importer, distributor, PRRC or RAQA professional, this episode will help you avoid mistakes and stay compliant with the latest medical device regulations. 👉 Listen now and stay updated on regulatory affairs for medical devices.

#MedicalDevices #RegulatoryAffairs #MDR745 #EUDAMED #MedicalDeviceCompliance #HealthcareRegulation #RAQA #PRRC]]>264italy,medicaldevicesfalse217fullhttps://www.spreaker.com/episode/top-registration-mistakes-that-could-cost-your-medical-device-approval--67185936frequent mistakes made by companies and economic operators during the registration of medical devices.

From selecting the correct UDI code to properly designating the economic operator, we provide a clear and practical overview of the key issues to avoid in order to ensure a compliant and effective registration process.

A valuable episode for industry professionals looking to approach European regulations with greater confidence.]]>https://api.spreaker.com/episode/67185936Wed, 30 Jul 2025 07:30:36 +0000Di Renzo Regulatrory AffairsIn this episode, we examine the most https://www.direnzo.biz/it/en/errors-registration-medical-devices/ made by companies and economic operators during the registration of medical devices. From selecting the correct UDI code to properly designating...frequent mistakes made by companies and economic operators during the registration of medical devices.

From selecting the correct UDI code to properly designating the economic operator, we provide a clear and practical overview of the key issues to avoid in order to ensure a compliant and effective registration process.

A valuable episode for industry professionals looking to approach European regulations with greater confidence.]]>496medicaldevice,regulatoryaffairsfalse216fullhttps://www.spreaker.com/episode/local-pharmacovigilance-all-requirements-how-to-be-compliant--67109936
Today, we’re focusing on a crucial subject for all Marketing Authorisation Holders: Local Pharmacovigilance.

It’s a vital system to ensure patient safety and regulatory compliance — often underestimated, but absolutely essential across the European landscape.

What does it take to set up an effective local pharmacovigilance network? What are the specific responsibilities of Marketing Authorisation Holders?

And how can an experienced partner like Di Renzo Regulatory Affairs support companies in managing these obligations?

We’ll cover all of this in today’s episode — clarifying roles, regulatory requirements, and practical solutions in the field of local pharmacovigilance. Stay with us!]]>https://api.spreaker.com/episode/67109936Fri, 25 Jul 2025 10:27:06 +0000Di Renzo Regulatrory AffairsWelcome to a new episode of the Di Renzo Regulatory Affairs podcast, where we explore key topics from the world of pharmaceutical regulatory affairs — with clarity, professionalism, and a practical approach. Today, we’re focusing on a crucial subject...
Today, we’re focusing on a crucial subject for all Marketing Authorisation Holders: Local Pharmacovigilance.

It’s a vital system to ensure patient safety and regulatory compliance — often underestimated, but absolutely essential across the European landscape.

What does it take to set up an effective local pharmacovigilance network? What are the specific responsibilities of Marketing Authorisation Holders?

And how can an experienced partner like Di Renzo Regulatory Affairs support companies in managing these obligations?

We’ll cover all of this in today’s episode — clarifying roles, regulatory requirements, and practical solutions in the field of local pharmacovigilance. Stay with us!]]>461local,pharmacovigilance,regulatoryaffairsfalse215fullhttps://www.spreaker.com/episode/is-our-software-a-medical-device--66834236How to understand if the software is a medical device?” we dissect the critical concept of intended medical purpose—diagnosis, prevention, monitoring, or treatment—and how it transforms standalone software into a regulated medical device.

If you're developing health-focused software—whether it's tracking patient metrics, analyzing data, or offering diagnostic support—this episode guides you through the essential criteria: does your tool carry an intended medical use? If yes, you need to treat it as a medical device: from EU MDR classification to validation and regulatory obligations.

By the end, you'll confidently answer: “Is our software a medical device?”, and know the steps to bring it to market.]]>https://api.spreaker.com/episode/66834236Wed, 02 Jul 2025 14:00:58 +0000Di Renzo Regulatrory AffairsIn this episode of the Di Renzo Regulatory Affairs Podcast, we explore a question at the heart of digital health compliance: When does your software become a medical device? Drawing from our latest article “How to understand if the software is a...How to understand if the software is a medical device?” we dissect the critical concept of intended medical purpose—diagnosis, prevention, monitoring, or treatment—and how it transforms standalone software into a regulated medical device.

If you're developing health-focused software—whether it's tracking patient metrics, analyzing data, or offering diagnostic support—this episode guides you through the essential criteria: does your tool carry an intended medical use? If yes, you need to treat it as a medical device: from EU MDR classification to validation and regulatory obligations.

By the end, you'll confidently answer: “Is our software a medical device?”, and know the steps to bring it to market.]]>1029false214fullhttps://www.spreaker.com/episode/labelling-pharmaceutical-sectors--66490565medicinal product labelling—a cornerstone of patient safety and regulatory compliance. We’ll explore:

• Evolving EU requirements: product names, active substances, strengths, and routes of administration;
• The impact of 2D QR codes and Braille: innovations for inclusive and accessible communication;
• The regulatory evolution of multilingual labelling: how to manage multi-language content while maintaining clarity and compliance;
• Operational challenges and practical solutions: from label design to approval, with a focus on version control and content consistency.

This episode is tailored for regulatory affairs, quality, and packaging professionals. Expect real-life examples, best practices, and key insights to navigate complexity efficiently—reducing risk and speeding up time to market.

Why listen:

• Stay up to date with evolving regulations and global trends.
• Gain actionable strategies to streamline internal processes—from creation to approval.
• Strengthen product quality and safety, a key differentiator in a competitive market.

Get ready to decode medicinal labelling like never before: where technology, regulation, and accessibility come together to ensure that every patient receives the right information, the right way.]]>https://api.spreaker.com/episode/66490565Tue, 10 Jun 2025 09:21:25 +0000Di Renzo Regulatrory AffairsJoin us in this episode as we delve into the complex world of medicinal product labelling—a cornerstone of patient safety and regulatory compliance. We’ll explore: - Evolving EU requirements: product names, active substances, strengths, and routes of...medicinal product labelling—a cornerstone of patient safety and regulatory compliance. We’ll explore:

• Evolving EU requirements: product names, active substances, strengths, and routes of administration;
• The impact of 2D QR codes and Braille: innovations for inclusive and accessible communication;
• The regulatory evolution of multilingual labelling: how to manage multi-language content while maintaining clarity and compliance;
• Operational challenges and practical solutions: from label design to approval, with a focus on version control and content consistency.

This episode is tailored for regulatory affairs, quality, and packaging professionals. Expect real-life examples, best practices, and key insights to navigate complexity efficiently—reducing risk and speeding up time to market.

Why listen:

• Stay up to date with evolving regulations and global trends.
• Gain actionable strategies to streamline internal processes—from creation to approval.
• Strengthen product quality and safety, a key differentiator in a competitive market.

Get ready to decode medicinal labelling like never before: where technology, regulation, and accessibility come together to ensure that every patient receives the right information, the right way.]]>856biocides,cosmetics,labelling,medicaldevices,pharmaceuticalfalse213fullhttps://www.direnzo.biz/it/en/cosmetic-labelling-2025/
🧴 Which pieces of information are mandatory, and what mistakes should be avoided at all costs?

In this episode, our experts walk you through the 7 key rules for correctly labeling a cosmetic product under Regulation (EC) No. 1223/2009. It’s a must-listen guide for companies, industry professionals, and anyone working in the cosmetics field.

🔍 From identifying the Responsible Person, to correctly using INCI nomenclature, to including proper environmental and safety indications — each point will help you navigate regulatory requirements with confidence.

🎧 Tune in to discover how labeling can become a powerful tool for compliance, transparency, and consumer trust.

📍 Available on Spotify, Apple Podcasts, and all major platforms. ]]>https://api.spreaker.com/episode/66292024Fri, 30 May 2025 05:00:07 +0000Di Renzo Regulatrory Affairs🎙️ New episode of the Di Renzo Regulatory Affairs podcast! Today we’re diving into a topic that is often underestimated but absolutely essential in the cosmetics sector: labeling. 📦 What does a label need to include to be considered compliant? 🧴...
🧴 Which pieces of information are mandatory, and what mistakes should be avoided at all costs?

In this episode, our experts walk you through the 7 key rules for correctly labeling a cosmetic product under Regulation (EC) No. 1223/2009. It’s a must-listen guide for companies, industry professionals, and anyone working in the cosmetics field.

🔍 From identifying the Responsible Person, to correctly using INCI nomenclature, to including proper environmental and safety indications — each point will help you navigate regulatory requirements with confidence.

🎧 Tune in to discover how labeling can become a powerful tool for compliance, transparency, and consumer trust.

📍 Available on Spotify, Apple Podcasts, and all major platforms. ]]>425cosmetics,label,rulesfalse212fullhttps://www.direnzo.biz/it/en/importance-statistics-medical-devices/statistical analysis in the post-market surveillance of medical devices.

We discuss how the collection and interpretation of data help ensure the safety and effectiveness of devices once they enter the market.

We delve into the statistical methodologies used, common challenges, and best practices for effective monitoring in compliance with European regulations.]]>https://api.spreaker.com/episode/66198568Thu, 22 May 2025 08:39:37 +0000Di Renzo Regulatrory AffairsIn this episode, we explore the crucial role of https://www.direnzo.biz/it/en/importance-statistics-medical-devices/ of medical devices. We discuss how the collection and interpretation of data help ensure the safety and effectiveness of devices once...statistical analysis in the post-market surveillance of medical devices.

We discuss how the collection and interpretation of data help ensure the safety and effectiveness of devices once they enter the market.

We delve into the statistical methodologies used, common challenges, and best practices for effective monitoring in compliance with European regulations.]]>396medicaldevices,statisticsfalse211fullhttps://www.spreaker.com/episode/food-supplements-regulation-in-italy--66054394Today, we’ll take a journey through time to explore the regulatory history of food supplements, a constantly evolving sector that is becoming increasingly relevant for both the industry and consumers.

Starting from the 1980s up to the current European regulatory framework, we'll examine how the very concept of a “supplement” has developed, the key milestones in the legislative path, and the main regulatory challenges faced today.

The episode is based on an article published by Di Renzo Regulatory Affairs, which you can find on their website — but here, we’ll walk you through the key points, with insights and reflections for professionals in the field or anyone curious to learn more. Would you like me to translate the teaser for social media as well?]]>https://api.spreaker.com/episode/66054394Thu, 15 May 2025 07:39:21 +0000Di Renzo Regulatrory AffairsWelcome to a new episode of our podcast dedicated to the world of pharmaceutical regulatory affairs. Today, we’ll take a journey through time to explore the regulatory history of food supplements, a constantly evolving sector that is becoming...Today, we’ll take a journey through time to explore the regulatory history of food supplements, a constantly evolving sector that is becoming increasingly relevant for both the industry and consumers.

Starting from the 1980s up to the current European regulatory framework, we'll examine how the very concept of a “supplement” has developed, the key milestones in the legislative path, and the main regulatory challenges faced today.

The episode is based on an article published by Di Renzo Regulatory Affairs, which you can find on their website — but here, we’ll walk you through the key points, with insights and reflections for professionals in the field or anyone curious to learn more. Would you like me to translate the teaser for social media as well?]]>394false210fullhttps://www.spreaker.com/episode/what-companies-should-know-about-pmcs-and-biocidal-products--66014657
The directive introduces a comprehensive evaluation of active substances, categorizing biocidal products into 23 distinct types and necessitating rigorous assessments, including toxicological and ecotoxicological studies. This transformation presents significant challenges for companies, especially those navigating the complexities of dossier preparation and compliance during the transitional phase

Di Renzo Regulatory Affairs offers expert guidance to companies, assisting in feasibility studies, regulatory intelligence, and the preparation of comprehensive dossiers to facilitate a smooth transition from PMCs to biocides.

Tune in to gain valuable insights into adapting to these regulatory changes and ensuring your products meet the new European standards. 🔗 Read the full article]]>https://api.spreaker.com/episode/66014657Fri, 09 May 2025 12:05:33 +0000Di Renzo Regulatrory Affairs🎙️ New Podcast Episode: Navigating the Transition from PMCs to Biocides In our latest episode, we delve into the evolving regulatory landscape surrounding Presidi Medico Chirurgici (PMCs) and their transition to biocidal products within the European...
The directive introduces a comprehensive evaluation of active substances, categorizing biocidal products into 23 distinct types and necessitating rigorous assessments, including toxicological and ecotoxicological studies. This transformation presents significant challenges for companies, especially those navigating the complexities of dossier preparation and compliance during the transitional phase

Di Renzo Regulatory Affairs offers expert guidance to companies, assisting in feasibility studies, regulatory intelligence, and the preparation of comprehensive dossiers to facilitate a smooth transition from PMCs to biocides.

Tune in to gain valuable insights into adapting to these regulatory changes and ensuring your products meet the new European standards. 🔗 Read the full article]]>422biocidal,disinfectant,pmc,regulatoryaffairsfalse29fullhttps://www.direnzo.biz/it/en/pharmacovigilance-responsibility/Regulatory Affairs & Life Science, your go-to space for deep dives into the pharmaceutical world—where regulations, innovation, and public health protection meet. Today, we’re tackling a crucial and complex topic: responsibility in pharmacovigilance.

Who is truly accountable for the safety of medicines once they’re on the market? What are the roles of pharmaceutical companies, Qualified Persons for Pharmacovigilance (QPPVs), and regulatory authorities?

Starting from an insightful analysis by Di Renzo Regulatory Affairs, we’ll explore how the concept of responsibility in pharmacovigilance has evolved—from European regulations to the practical implications for companies in the field.

This is a must-listen episode for anyone working in regulatory affairs or anyone curious about how the safety of the medicines we use every day is monitored and ensured.

Stay with us…]]>https://api.spreaker.com/episode/65394902Mon, 07 Apr 2025 08:28:38 +0000Di Renzo Regulatrory AffairsWelcome to a new episode of Regulatory Affairs & Life Science, your go-to space for deep dives into the pharmaceutical world—where regulations, innovation, and public health protection meet. Today, we’re tackling a crucial and complex topic:...Regulatory Affairs & Life Science, your go-to space for deep dives into the pharmaceutical world—where regulations, innovation, and public health protection meet. Today, we’re tackling a crucial and complex topic: responsibility in pharmacovigilance.

Who is truly accountable for the safety of medicines once they’re on the market? What are the roles of pharmaceutical companies, Qualified Persons for Pharmacovigilance (QPPVs), and regulatory authorities?

Starting from an insightful analysis by Di Renzo Regulatory Affairs, we’ll explore how the concept of responsibility in pharmacovigilance has evolved—from European regulations to the practical implications for companies in the field.

This is a must-listen episode for anyone working in regulatory affairs or anyone curious about how the safety of the medicines we use every day is monitored and ensured.

Stay with us…]]>416lifescience,pharmacovigilancefalse28fullhttps://www.spreaker.com/episode/the-use-of-data-mining-in-pmcf-data-analysis-and-real-world-questionnaires--65178752data mining in the medical device sector. 

Data mining is a set of advanced techniques that allow us to extract meaningful insights from data collected during the use of medical devices. These insights are crucial for improving safety, effectiveness, and innovation in the medical field. 

Today, we will delve into how post-market data analysis and real-world questionnaires can benefit from data mining, helping us better understand the real-world performance of medical devices.
 
Additionally, we will discuss regulatory implications and the challenges companies face when implementing these techniques.  

Stay with us to discover how data mining is revolutionizing the landscape of medical devices!
]]>https://api.spreaker.com/episode/65178752Fri, 28 Mar 2025 08:29:17 +0000Di Renzo Regulatrory AffairsWelcome to this episode of our podcast, where we explore the application of https://www.direnzo.biz/it/en/data-mining-pmcf/.  Data mining is a set of advanced techniques that allow us to extract meaningful insights from data collected during the use...data mining in the medical device sector. 

Data mining is a set of advanced techniques that allow us to extract meaningful insights from data collected during the use of medical devices. These insights are crucial for improving safety, effectiveness, and innovation in the medical field. 

Today, we will delve into how post-market data analysis and real-world questionnaires can benefit from data mining, helping us better understand the real-world performance of medical devices.
 
Additionally, we will discuss regulatory implications and the challenges companies face when implementing these techniques.  

Stay with us to discover how data mining is revolutionizing the landscape of medical devices!
]]>395datamining,medicaldevicesfalse26fullhttps://www.direnzo.biz/it/en/concerns-medical-device-industry/increasing challenges due to the regulatory changes introduced by IVDR and MDR. In this episode, we analyze the impact of these regulations on costs, innovation, and market access, exploring manufacturers' concerns and potential solutions for the future. A must-listen for companies, industry professionals, and anyone looking to better understand the dynamics of an ever-evolving market.]]>https://api.spreaker.com/episode/64493206Fri, 21 Feb 2025 11:52:01 +0000Di Renzo Regulatrory AffairsOver the past seven years, the medical device industry has faced increasing challenges due to the regulatory changes introduced by IVDR and MDR. In this episode, we analyze the impact of these regulations on costs, innovation, and market access,...increasing challenges due to the regulatory changes introduced by IVDR and MDR. In this episode, we analyze the impact of these regulations on costs, innovation, and market access, exploring manufacturers' concerns and potential solutions for the future. A must-listen for companies, industry professionals, and anyone looking to better understand the dynamics of an ever-evolving market.]]>452mdr,medicaldevices,regulationfalse25fullhttps://www.spreaker.com/episode/the-role-of-statistics-in-the-drafting-of-a-post-market-clinical-follow-up-pmcf-plan-for-medical-devices--64376790statistics in drafting the Post-Market Clinical Follow-Up (PMCF) plan for medical devices.

We explore how planning a PMCF study requires an accurate determination of sample size, based on identifying the target population and the prevalence of relevant events.

We discuss the importance of data analysis, carried out using advanced statistical software such as R, SAS, or SPSS, and the application of appropriate statistical tests to assess parameters such as clinical effectiveness or user satisfaction.

Additionally, we address uncertainty management through statistical tools like confidence intervals and hypothesis testing, which are essential for quantifying the variability of data collected in real-world settings.

Finally, we emphasize the importance of clear and transparent communication of results, supported by appropriate visualizations, to ensure proper interpretation of the study’s conclusions.
]]>https://api.spreaker.com/episode/64376790Fri, 14 Feb 2025 13:27:08 +0000Di Renzo Regulatrory AffairsIn the new episode of our podcast, we delve into the crucial role of https://www.direnzo.biz/it/en/statistics-pmcf/ (PMCF) plan for medical devices. We explore how planning a PMCF study requires an accurate determination of sample size, based on...statistics in drafting the Post-Market Clinical Follow-Up (PMCF) plan for medical devices.

We explore how planning a PMCF study requires an accurate determination of sample size, based on identifying the target population and the prevalence of relevant events.

We discuss the importance of data analysis, carried out using advanced statistical software such as R, SAS, or SPSS, and the application of appropriate statistical tests to assess parameters such as clinical effectiveness or user satisfaction.

Additionally, we address uncertainty management through statistical tools like confidence intervals and hypothesis testing, which are essential for quantifying the variability of data collected in real-world settings.

Finally, we emphasize the importance of clear and transparent communication of results, supported by appropriate visualizations, to ensure proper interpretation of the study’s conclusions.
]]>586mdr,medicaldevice,pmcf,pmcfplaningfalse24fullhttps://www.spreaker.com/episode/good-clinical-practice-new-version-published--63877456New Podcast Episode: Clinical Trials and the New GCP E6(R3) Guidelines

💊 Clinical trials are a cornerstone of developing safe and effective therapies, ensuring compliance with ethical and scientific standards.

But how is this process evolving with the latest regulatory innovations? In this episode, we delve into the updates introduced by the Guideline for Good Clinical Practice (GCP) E6(R3), published by the International Council for Harmonisation (ICH) on January 6, 2025. 🔍 Topics include:

• Key updates compared to the previous E6(R2) version.
• How these changes enhance the quality and efficiency of clinical trials.
• The impact of new technologies on clinical research.
• The role of EU Regulation 2014/536 in ensuring regulatory harmonization across Europe.

💡 This episode is tailored for professionals and companies in the pharmaceutical sector who want to stay up-to-date with the latest developments and regulations in clinical research. 📲 Listen now to learn more: Clinical Trials Podcast Don’t miss this opportunity to explore a critical topic shaping the future of research and therapeutic development! 🌍]]>https://api.spreaker.com/episode/63877456Fri, 24 Jan 2025 15:36:31 +0000Di Renzo Regulatrory Affairs🎙 New Podcast Episode: Clinical Trials and the New GCP E6(R3) Guidelines 💊 Clinical trials are a cornerstone of developing safe and effective therapies, ensuring compliance with ethical and scientific standards. But how is this process evolving...New Podcast Episode: Clinical Trials and the New GCP E6(R3) Guidelines

💊 Clinical trials are a cornerstone of developing safe and effective therapies, ensuring compliance with ethical and scientific standards.

But how is this process evolving with the latest regulatory innovations? In this episode, we delve into the updates introduced by the Guideline for Good Clinical Practice (GCP) E6(R3), published by the International Council for Harmonisation (ICH) on January 6, 2025. 🔍 Topics include:

• Key updates compared to the previous E6(R2) version.
• How these changes enhance the quality and efficiency of clinical trials.
• The impact of new technologies on clinical research.
• The role of EU Regulation 2014/536 in ensuring regulatory harmonization across Europe.

💡 This episode is tailored for professionals and companies in the pharmaceutical sector who want to stay up-to-date with the latest developments and regulations in clinical research. 📲 Listen now to learn more: Clinical Trials Podcast Don’t miss this opportunity to explore a critical topic shaping the future of research and therapeutic development! 🌍]]>316clinical,trialsfalse23fullhttps://www.direnzo.biz/it/en/professional-drug-sector/In this episode, we discuss the new professional roles in the pharmaceutical sector. We analyze how transformations in the industry, driven by technological innovation and increasingly complex regulations, are creating opportunities for unique and highly specialized roles.

What are the most in-demand skills?
How is the job market evolving in the pharmaceutical field?If you’re interested in exploring the new frontiers of this industry and discovering career opportunities in this field, this episode is a must-listen!

Tune in now and find out how the pharmaceutical sector is reshaping the job market.]]>https://api.spreaker.com/episode/63726547Fri, 17 Jan 2025 13:47:18 +0000Di Renzo Regulatrory Affairs🎙 New episode of our podcast! In this episode, we discuss the https://www.direnzo.biz/it/en/professional-drug-sector/. We analyze how transformations in the industry, driven by technological innovation and increasingly complex regulations, are...In this episode, we discuss the new professional roles in the pharmaceutical sector. We analyze how transformations in the industry, driven by technological innovation and increasingly complex regulations, are creating opportunities for unique and highly specialized roles.

What are the most in-demand skills?
How is the job market evolving in the pharmaceutical field?If you’re interested in exploring the new frontiers of this industry and discovering career opportunities in this field, this episode is a must-listen!

Tune in now and find out how the pharmaceutical sector is reshaping the job market.]]>613pharmaceutical,workfalse22fullhttps://www.direnzo.biz/it/en/conferences-congresses/organize meetings, conferences, or scientific events, both in Italy and abroad.

We’ll delve into the key regulations and compliance requirements that must be met, with a particular focus on events related to the promotion of medicinal products manufactured or marketed by the same company.

In Italy, the law establishes specific procedures to ensure transparency and integrity, preventing conflicts of interest and safeguarding the quality of disseminated information. Among these is the obligation to obtain prior authorization from the Italian Medicines Agency (AIFA), which must be requested at least 60 days before the event begins, as outlined in Article 124 of Legislative Decree 219/06.

If your company is planning a scientific event, this episode will guide you through the requirements and steps necessary to ensure regulatory compliance. ]]>https://api.spreaker.com/episode/63601087Tue, 07 Jan 2025 14:36:11 +0000Di Renzo Regulatrory AffairsThis episode of the podcast is tailored for pharmaceutical companies planning to organize meetings, conferences, or scientific events, both in Italy and abroad. We’ll delve into the key regulations and compliance requirements that must be met, with a...organize meetings, conferences, or scientific events, both in Italy and abroad.

We’ll delve into the key regulations and compliance requirements that must be met, with a particular focus on events related to the promotion of medicinal products manufactured or marketed by the same company.

In Italy, the law establishes specific procedures to ensure transparency and integrity, preventing conflicts of interest and safeguarding the quality of disseminated information. Among these is the obligation to obtain prior authorization from the Italian Medicines Agency (AIFA), which must be requested at least 60 days before the event begins, as outlined in Article 124 of Legislative Decree 219/06.

If your company is planning a scientific event, this episode will guide you through the requirements and steps necessary to ensure regulatory compliance. ]]>527congress,information,pharmaceuticalfalse21fullhttps://www.spreaker.com/episode/parallel-importation-of-medical-devices--62737484Article 16 represents a major advancement in the regulation of parallel imports, providing more clarity and detail than previous regulations. Specifically, it:

• Clearly defines what constitutes a parallel import of a medical device.
• Underscores the critical importance of adherence to essential requirements and harmonized standards.
• Imposes specific obligations on parallel importers, including verification of technical documentation and device traceability.
• Allows for corrective and safety measures to be taken in the event of non-compliance.

]]>https://api.spreaker.com/episode/62737484Thu, 14 Nov 2024 13:08:31 +0000Di Renzo Regulatrory AffairsThe Importance of Article 16 of the MDR Article 16 represents a major advancement in the https://www.direnzo.biz/it/en/parallel-imports-medical-devices/, providing more clarity and detail than previous regulations. Specifically, it: - Clearly defines...Article 16 represents a major advancement in the regulation of parallel imports, providing more clarity and detail than previous regulations. Specifically, it:

• Clearly defines what constitutes a parallel import of a medical device.
• Underscores the critical importance of adherence to essential requirements and harmonized standards.
• Imposes specific obligations on parallel importers, including verification of technical documentation and device traceability.
• Allows for corrective and safety measures to be taken in the event of non-compliance.

]]>440import,medicaldevices,parallelfalse13fullhttps://www.spreaker.com/episode/qppv-a-guardian-of-drug-safety--62652769Pharmacovigilance Qualified Person (QPPV). We'll explore their responsibilities, qualifications, and the importance of their role in ensuring patient safety. From setting up pharmacovigilance systems to managing risk assessments and responding to regulatory inquiries, the QPPV plays a pivotal role in the post-marketing surveillance of medications.]]>https://api.spreaker.com/episode/62652769Thu, 07 Nov 2024 13:53:49 +0000Di Renzo Regulatrory AffairsIn this episode, we delve into the crucial role of the https://www.direnzo.biz/it/en/qppv-task-responsibilities/ (QPPV). We'll explore their responsibilities, qualifications, and the importance of their role in ensuring patient safety. From setting up...Pharmacovigilance Qualified Person (QPPV). We'll explore their responsibilities, qualifications, and the importance of their role in ensuring patient safety. From setting up pharmacovigilance systems to managing risk assessments and responding to regulatory inquiries, the QPPV plays a pivotal role in the post-marketing surveillance of medications.]]>379pharmacovigilance,qppvfalse12fullhttps://www.spreaker.com/episode/regulation-eu-2017-745-mdr--60765830medical device regulation, it is crucial to stay up-to-date. That's why today we'll delve into Regulation (EU) 2023/607, a significant amendment to Regulation (EU) 2017/745 (MDR) that introduces an extension of the transition period and defines the criteria for benefiting from it.As Regulatory Affairs experts dedicated to Class I medical devices, Di Renzo Regulatory Affairs is ready to support manufacturers in this delicate transition process.In this podcast, we will guide you through the details of Regulation 2023/607, clarifying:

• Which Class I medical devices are eligible for the extension
• How to correctly assess the classification of your device
• What are the specific timelines for the extension
• How to make the most of this additional period to prepare for the MDR

By listening to this podcast, you will gain the knowledge you need to confidently navigate the new regulations and plan a smooth and efficient transition to the MDR.Stay tuned to discover how Di Renzo Regulatory Affairs can support your success in the new medical device regulatory framework!Here are some additional points that you may want to include in your podcast intro:

• Introduce Di Renzo Regulatory Affairs and its expertise in medical device regulation.
• Highlight the importance of the MDR and its impact on Class I medical device manufacturers.
• Emphasize the value of Di Renzo Regulatory Affairs' services in helping manufacturers comply with the MDR.
• Encourage listeners to subscribe to the podcast and leave reviews.

I hope this is helpful!]]>https://api.spreaker.com/episode/60765830Mon, 22 Jul 2024 12:56:01 +0000Di Renzo Regulatrory AffairsWelcome to the new Di Renzo Regulatory Affairs podcast!In the ever-evolving landscape of medical device regulation, it is crucial to stay up-to-date. That's why today we'll delve into Regulation (EU) 2023/607, a significant amendment to...medical device regulation, it is crucial to stay up-to-date. That's why today we'll delve into Regulation (EU) 2023/607, a significant amendment to Regulation (EU) 2017/745 (MDR) that introduces an extension of the transition period and defines the criteria for benefiting from it.As Regulatory Affairs experts dedicated to Class I medical devices, Di Renzo Regulatory Affairs is ready to support manufacturers in this delicate transition process.In this podcast, we will guide you through the details of Regulation 2023/607, clarifying:

• Which Class I medical devices are eligible for the extension
• How to correctly assess the classification of your device
• What are the specific timelines for the extension
• How to make the most of this additional period to prepare for the MDR

By listening to this podcast, you will gain the knowledge you need to confidently navigate the new regulations and plan a smooth and efficient transition to the MDR.Stay tuned to discover how Di Renzo Regulatory Affairs can support your success in the new medical device regulatory framework!Here are some additional points that you may want to include in your podcast intro:

• Introduce Di Renzo Regulatory Affairs and its expertise in medical device regulation.
• Highlight the importance of the MDR and its impact on Class I medical device manufacturers.
• Emphasize the value of Di Renzo Regulatory Affairs' services in helping manufacturers comply with the MDR.
• Encourage listeners to subscribe to the podcast and leave reviews.

I hope this is helpful!]]>418consultancy,mdr,medicaldevicesfalse11full